

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following HR-positive/HER2-negative breast cancer patient subgroups is not validated for prediction of recurrence with the RSClin educational tool?**
  - a. Patients with lymph node positive disease
  - b. Patients under age 40
  - c. Patients who previously received chemotherapy
  - d. Patients with tumor size >2cm
- 2. Mature safety findings from the monarchE trial revealed the occurrence of which of the following adverse events was not increased with abemaciclib and endocrine therapy versus endocrine therapy alone for patients with HR-positive, HER2-negative breast cancer?**
  - a. Diarrhea
  - b. Fatigue
  - c. Neutropenia
  - d. Arthralgia
- 3. Which of the following is not a known mechanism of resistance to CDK4/6 inhibitors for patients with HR-positive breast cancer?**
  - a. Alterations in cell-cycle machinery
  - b. Aberrations in PI3K/AKT/mTOR pathways
  - c. FGFR signaling alterations
  - d. Loss of PD-L1 expression
- 4. Which of the following best describes the mechanism of action of the novel agent giredestrant (GDC-9545) under investigation for patients with ER-positive metastatic breast cancer?**
  - a. Oral selective estrogen receptor degrader
  - b. CDK4/6 inhibitor
  - c. LIV-1-directed antibody drug conjugate
  - d. EGFR-directed antibody drug conjugate